Peptide 14
2 papers study it4 findings
Across all fields, 2 papers: 1 trial in people, 1 in cells
- 1 lab in 1 country
- Funders: Conselho Nacional de Desenvolvimento Científico e Tecnológico and 6 more
- Human trial1
- Cells1
Outcomes
4Epigenetic age
downin human cells1
1 study
Epigenetic age
downin human cells1
Peptide 14 decreases epigenetic age in human cells.
“reduced the DNA methylation age”
Cellsskin
Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models
npj aging
Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
Peptide 14 decreases cellular senescence in human cells.
“Pep 14 effectively decreased human dermal fibroblast senescence burden induced by Hutchinson-Gilford Progeria Syndrome (HGPS), chronological aging, ultraviolet-B radiation (UVB), and etoposide treatment”
Cellsinduced by HGPS, chronological aging, UVB, and etoposidedermal fibroblast
Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models
npj aging
Skin irritation
no changein humans1
1 study
Skin irritation
no changein humans1
Peptide 14 has no effect on skin irritation in humans.
“No visible skin reactions were observed in any of the 54 participants.”
Human trialskin1 mMn = 54
In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14
Toxicology reports
Cellular toxicity
no changein human cells1
1 study
Cellular toxicity
no changein human cells1
Peptide 14 has no effect on cellular toxicity in human cells.
“show that it is mostly non-toxic in concentrations up to 100 μM”
Cellsup to 100 μM
In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14
Toxicology reports